Search form

Search form

Celgene plans to "enforce its extensive intellectual property rights" on multiple myeloma drug Revlimid after an unnamed drugmaker filed for FDA approval of a generic version. The treatment is covered by 12 patents, with expiration as far out as 2026. Celgene has not received formal notice of the generic challenge.

Related Summaries

Celgene filed a lawsuit against Natco Pharma after the latter sought FDA approval to market a generic version of Revlimid, the former's treatment for multiple myeloma. Celgene said Natco's copy would infringe on 10 patents that expire between 2016 and 2026.

Celgene filed a lawsuit against Natco Pharma after the latter sought FDA approval to market a generic version of Revlimid, the former's treatment for multiple myeloma. Celgene said Natco's copy would infringe on 10 patents that expire between 2016 and 2026.

Celgene filed a lawsuit against Natco Pharma after the latter sought FDA approval to market a generic version of Revlimid, the former's treatment for multiple myeloma. Celgene said Natco's copy would infringe on 10 patents that expire between 2016 and 2026.

U.S. District Judge Emmet Sullivan denied a request by Sanofi-Aventis to prevent an FDA-approved copy of its blood thinner Lovenox from going into the market. The generic was developed by Novartis' Sandoz subsidiary and Momenta Pharmaceuticals. The judge said delaying the distribution of the generic could have a negative effect on the public.

Celgene plans to "enforce its extensive intellectual property rights" on multiple myeloma drug Revlimid after an unnamed drugmaker filed for FDA approval of a generic version. The treatment is covered by 12 patents, with expiration as far out as 2026. Celgene has not received formal notice of the generic challenge.